ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1126

A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study

Dana DiRenzo1, Carly Hunt2, Erica Sibinga2, Neda Gould2, Ami Shah3, Susan Bartlett4 and Clifton Bingham III1, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, 3Johns Hopkins University School of Medicine, Ellicott City, MD, 4McGill University, Montreal, Canada

Meeting: ACR Convergence 2020

Keywords: health behaviors, mental health, Patient reported outcomes, psychosocial factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Mindfulness Based Interventions (MBIs) are well-established self-management programs shown to be beneficial for pain, depression, and anxiety that focus on learning how to respond to bodily sensations and emotions through guided meditative practices. However, due to time constraints, scheduling, and physical limitations, we found it difficult for patients to attend in-person MBIs; we therefore implemented a mobile MBI, using the commercially available smartphone application, Calm©.

Methods: Established patients with rheumatic disease in our Rheumatology Division at a tertiary referral center were eligible for inclusion. Participants were asked to engage in the app for a minimum of 5 minutes/day for 30 days,  provide baseline clinical and demographic information, and complete baseline and 30-day questionnaires pertaining to health-related quality of life (HRQL). Questionnaires included the Patient Reported Outcome Measurement Information System (PROMIS) (v2.0) 4a short forms (physical function, social participation, fatigue, sleep disturbance, pain interference), computer adaptive tests (CATS) (v1.0) for anxiety, depression, self-efficacy for managing emotions, and for managing symptoms and the NIH Toolbox Perceived Stress FF v2.0. Demographics, clinical characteristics, and mean T-scores were compared between groups using t-tests or chi-square. A sensitivity analysis was performed for participants who fully completed the program.

Results: 40 participants consented, 35 participants completed baseline questionnaires, 17 participants completed post survey questionnaires and used Calm, 17 participants completed baseline questionnaires but were lost to follow up, and 1 participant completed both surveys but did not use Calm. Participants had a mean age (SD) of 50 years (13), were mostly female (91%), white (74%), well-educated (66% with a college degree or greater) and working full time (56%). Most participants had inflammatory arthritis (60%); patients with lupus (17%), Sjogren’s syndrome (9%), and scleroderma (14%) were also included. Compared to non-completers, full completers had similar demographics and use of medications that could potentially impact mood. However, full completers had higher patient global assessment of disease activity (PGA) scores, more pain (VAS), higher perceived stress, and more anxiety at baseline (Table 1). Full completers meditated on average for 302 minutes (SD 254; n=15). For completers, significant improvements were noted in fatigue by course end with trends for improvement in perceived stress, anxiety, sleep disturbance, and self-efficacy (Table 2).

Conclusion: Results from a pilot study on use of a 30-day smartphone mindfulness meditation application for patients with rheumatic disease revealed that this is a feasible and acceptable non-pharmacologic modality to target HRQL. Participants with higher baseline stress, anxiety, pain, and PGA scores were more likely to complete the mobile MBI program. Among completers, preliminary results showed improvements in fatigue and perceived stress. More rigorous study on mindfulness application use and barriers, as well as potential effect on HRQL, is needed.

Table 1. Baseline patient characteristics comparing those who completed the full program compared to those lost to follow up.

Table 2. HRQL domains pre/post 30-day mobile, mindfulness meditation trial for participants who completed pre/post questionnaires (n=18). * Derived from PROMIS 4a form extracted from Global-29 collection of surveys; **CATs, ***NIH Fixed Form.


Disclosure: D. DiRenzo, None; C. Hunt, None; E. Sibinga, None; N. Gould, None; A. Shah, None; S. Bartlett, Pfizer, 1, UCB, 1, Lily, 1, Novartis, 1, Merck, 1, Janssen, 1, Abbvie, 1; C. Bingham III, Bristol-Myers Squibb, 2, 5, 8, Genetech, 5, 8, Sanofi, 5, 8, AbbVie, 5, Eli Lilly, 5, Pfizer, 5, Gilead Sciences, Inc., 5, Regeneron, 5.

To cite this abstract in AMA style:

DiRenzo D, Hunt C, Sibinga E, Gould N, Shah A, Bartlett S, Bingham III C. A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-mobile-mindfulness-meditation-program-may-improve-health-related-quality-of-life-for-patients-with-rheumatic-disease-a-pilot-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-mobile-mindfulness-meditation-program-may-improve-health-related-quality-of-life-for-patients-with-rheumatic-disease-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology